Navigation Links
Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
Date:6/16/2008

Cato Research Signed as Strategic Partner for the Phase 3 Program

LA JOLLA, Calif., June 16 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company developing non-invasive, topically administered medications, today announced the initiation of its Phase 3 clinical program for Ketotransdel(TM), its novel topical cream based non-steroidal anti-inflammatory drug ("NSAID") for pain. The Company has engaged Cato Research Ltd., a global contract research organization ("CRO"), as a strategic partner and as the CRO to conduct the Phase 3 clinical program.

The Company's randomized, double-blind, placebo controlled Phase 3 trial will evaluate the efficacy and safety of Ketotransdel(TM) for the topical treatment of acute pain from soft tissue injuries. Clinical sites are planned throughout the United States and potentially other regions, including Canada. The Company expects that Ketotransdel(TM), if approved by the U.S. Food and Drug Administration, could become the first topical NSAID cream product in the United States for acute pain management. The drug could address what the Company believes is a significant unmet medical need for patients and physicians seeking a potentially safer alternative to existing pain management approaches, such as oral NSAIDs.

"Advancing Ketotransdel(TM) into Phase 3 clinical studies is a significant milestone for our Company. Our top priority is to execute our clinical program as planned," said Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals. "For the conduct of the clinical trial we carefully evaluated only select top level CROs with extensive experience in the relevant pain area. We selected Cato Research not only due to their relationship as a strategic partner with us, but because of their cost efficient approach to the clinical program, expertise in the pain space and our direct access to their senior executive man
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
5. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
6. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
7. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
10. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
11. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...v. 30 Nektar Therapeutic...f Lorianne Masuoka, M.D. to Senior Vice President ...t directly to Nektar,s President and Chief Executi...utstanding leadership and highly effective clinica... rapidly advancing Nektar,s proprietary clinical p...
(Date:11/30/2009)...wire/ -- Breast-Specific Gamma Imaging (BSGI) sign...t or high-risk lesions in patients with negative o...o results of a multicenter study presented today a...f North America (RSNA). ,, In this retrospectiv...ic imaging modality at four institutions and was c...
(Date:11/30/2009)...30 SCOLR Pharma, Inc. (N...25, 2009, the NYSE Amex LLC (the "Exchange") notif... plan to comply with its previously disclosed list...change Company Guide. Specifically, the deficienc...which were so substantial in relation to its overa...
Breaking Medicine Technology:Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer 2Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer 3BSGI Makes Significant Impact on Detection of Breast Cancer in Patients with Negative Mammographic Findings 2SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Analysis Sheds Light on Proteins Role in Cancer 48086 1Fatty foods not empty stomach fire up hunger hormone 8733 1Fatty foods not empty stomach fire up hunger hormone 8733 2Code Red for the Health Care System 48083 1Code Red for the Health Care System 48083 2Code Red for the Health Care System 48083 3
...asdaq: DRRX ) announced today that the US Food an...rug Application (NDA) of REMOXY(R) and granted,Pri...view to drug,candidates that have the potential to...marketed products. The FDA goal for completing rev...onths from the date the application was,submitted....
...ne, PRINCETON, N.J., Aug. 12 Medarex, Inc.,(Nasd...mune, Inc. has,initiated a Phase 2A multi-dose cli...t of systemic lupus erythematosus (SLE or lupus).,...darex,s UltiMAb Human,Antibody Development System(... receive a milestone payment of an undisclosed amo...
Other Medicine Technology:REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted 2REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted 3Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 3Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 4
(Date:12/1/2009)... Dec. 1 Abrazo Media Relations-- T... ( http:// www.pedsorthopaedics.com ) located in M... surgeon Dr. J. Hunt Udall to its practice. ,,...paedic surgery after recently completing his fello...ssachusetts where he focused on adult and pediatri...
(Date:12/1/2009)...r 2009. Performing surgical operations without le...ome a reality. This is demonstrated by the recent ...e Transluminal Endoscopy Surgery), an innovative s... the body,s natural orifices. The results are all ...er hospital stay and faster recovery. Currently, t...
(Date:12/1/2009)... California are unable to successfully obtain info...s despite recent state legislation intended to imp... , Posing as low-income uninsured patients, rese...e-third of the hospitals they approached and the e...e allowed under California law, according to the f...
(Date:12/1/2009)... system tied to academic achievement, study finds ... strong cardiovascular system in young adulthood m...es and more overall success later in life, new res...aypeople know (or should know) the benefits of exe...s of a new study, appearing in this week,s online ...
(Date:12/1/2009)...xas, Dec. 1 For many employers, th...s more than just an employee benefit, it,s providi...by Lobby Stores, Inc. is leading this effort, with...th and wellness center at its corporate offices, b...s directly to employees and their dependents. ,...
Breaking Medicine News(10 mins):Health News:Orthopaedic Surgeon Dr. J. Hunt Udall Joins the Center for Pediatric Orthopaedics and Scoliosis as One of Few Trained Doctors to Perform Minimally Invasive Hip Arthroscopy 2Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 2Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 3Health News:Hospital price transparancy laws in California fall short, study finds 2Health News:Exercise May Lead to a Smarter, More Successful You 2Health News:Exercise May Lead to a Smarter, More Successful You 3Health News:Hobby Lobby Selects Concentra to Open Health Center 2Health News:Hobby Lobby Selects Concentra to Open Health Center 3
...ew policy that significantly limits interactions w...and appropriate partnerships with drug and medical...ne Policy on Interaction with Industry, the policy...tists, students and staff may interact with indust...
...stbands had much less nausea while receiving radia...addition to anti-nausea medication, according to a...om Management by University of Rochester Medical ...n might be why elastic wristbands reduce nausea. ...
...youth are engaging in sexual intercourse as early ...The University of Texas School of Public Health. ...ril issue of Journal of School Health . , Chris...middle school students in a large southeastern U.S...
...Individuals How Much They Will Pay for Treatment a...hcare , , ANN ARBOR, Mich., April 8 As people ta...s cost, employers and health insurers need better ... challenge, HealthEquity has embedded Consumer Adv...
...gislators brainstorm ways to reduce significant le...ness continues to find innovative solutions to edu... and abuse. Innocorp President Michael Aguilar ann...y Outreach and Education Services. , , "Impaired ...
... PHILADELPHIA, April 8 Kyle,s Treehouse -- an o...nounces their new initiative for Autism Awareness ... and inspiration. Autism151 focuses on the posit..., giving them even more reasons to hope. , , ...
Other Medicine News:Health News:New JHM policies tighten rules on industry interactions 2Health News:New JHM policies tighten rules on industry interactions 3Health News:Wristbands ease nausea with cancer treatment 2Health News:Middle school youth as young as 12 engaging in risky sexual activity 2Health News:HealthEquity, a Leading Healthcare Account Administrator, Licenses Thomson Reuters Information Solutions to Help People Make Better Healthcare Decisions 2Health News:HealthEquity, a Leading Healthcare Account Administrator, Licenses Thomson Reuters Information Solutions to Help People Make Better Healthcare Decisions 3Health News:Former MADD National President Joins Innocorp, ltd. 2Health News:Kyle's Treehouse Launches Autism151.com for Autism Awareness Month 2
...first 192 channel simultaneous sampling EEG with 6...e for routine EEG exam rooms as well as epilepsy c...nal analysis software for automatic spike and seiz...leep analysis. Quality Data Acquisition ,The Ne...
... purchase an XLTEK Mobee, you're getting an ambula...bee32 and the Mobee O2 can be used for ambulatory ...al in-lab EEG monitoring, or in-lab sleep studies....ll 10/20 electrode placement. The Mobee O2 include...
Vision Monitor Visual Electrophysiology: MonEl1
...30 Slit Lamp is an all-in-one instrument for obser...Its optimally structured design also allows the SL...hieved by the possibility of operating the slit pr...ft or right hand. The instrument configuration all...
Medicine Products: